Dr. Jason Valentine

Cooley advised Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, on its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors.

Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company, on its oversubscribed $225 million Series C financing.

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised Obsidio in the development of its patent portfolio and in defending intellectual property diligence in its acquisition by global medical device company Boston Scientific. Obsidio’s Food and Drug Administration-cleared gel embolic material (GEM) technology is a semisolid material packaged in a ready-to-use form. The GEM technology was developed for embolization, a procedure that blocks blood vessels by using particles to stop bleeding or halt the flow of blood to a tumor or abnormal area of tissue.

“This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions,” said Peter Pattison, president of interventional oncology and embolization at Boston Scientific.